Astria Therapeutics, Inc.

Historical 13F Holders

Symbol
ATXS
CUSIP
04635X102
All holders as of
Q4 2025
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 04635X102 since 12/18/2024, newest first.

Filer % of Class Filed
Vestal Point Capital, LP 13G/A Amendment 2
0% 2/17/2026
Event 12/31/2025
Glazer Capital, LLC 13G/A Amendment 1
6.6% 2/12/2026
Event 12/31/2025
Perceptive Advisors LLC 13D/A Amendment 7
0% 2/9/2026
Event 1/26/2026
Magnetar Financial LLC 13D/A Amendment 1
0% 1/28/2026
Event 1/26/2026
Glazer Capital, LLC 13G
5.5% 12/10/2025
Event 12/3/2025
ForGrowth III PA B.V. 13G/A Amendment 1
0% 11/14/2025
Event 10/16/2025
Vestal Point Capital, LP 13G/A Amendment 1
8.8% 11/14/2025
Event 9/30/2025
FMR LLC 13G/A Amendment 8
2.2% 11/7/2025
Event 10/31/2025
FMR LLC 13G/A Amendment 7
9.1% 11/5/2025
Event 9/30/2025
Magnetar Financial LLC 13D
5.9% 10/24/2025
Event 10/17/2025
Integrated Core Strategies (US) LLC 13G/A Amendment 1
0.4% 10/20/2025
Event 10/14/2025
Perceptive Advisors LLC 13D/A Amendment 6
11.5% 10/16/2025
Event 10/14/2025
Fairmount Funds Management LLC 13G/A Amendment 7
4.0% 10/15/2025
Event 10/14/2025
RA Capital Management, L.P. 13G/A Amendment 2
0% 8/14/2025
Event 6/30/2025
Integrated Core Strategies (US) LLC 13G
5.2% 6/18/2025
Event 6/13/2025
ForGrowth III PA B.V. 13G/A Amendment 1
6.8% 5/15/2025
Event 3/31/2025
FMR LLC 13G/A Amendment 6
12.3% 5/12/2025
Event 3/31/2025
Venrock Healthcare Capital Partners III, L.P. 13G/A Amendment 2
4.4% 2/14/2025
Event 12/31/2024
Fairmount Funds Management LLC 13G/A Amendment 6
9.9% 2/14/2025
Event 12/31/2024
FMR LLC 13G/A Amendment 5
13.9% 2/12/2025
Event 12/31/2024
Integrated Core Strategies (US) LLC 13G/A Amendment 1
3.5% 1/28/2025
Event 12/31/2024
ForGrowth III PA B.V. 13G
5.1% 1/7/2025
Event 12/30/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2025 Q4 144 56.6 M $739 M
2025 Q3 122 59.2 M $421 M
2025 Q2 109 57.7 M $311 M
2025 Q1 121 58.4 M $312 M
2024 Q4 116 58.5 M $523 M
2024 Q3 109 56.6 M $622 M
2024 Q2 109 56.9 M $518 M
2024 Q1 130 58.1 M $817 M
2023 Q4 87 37.3 M $286 M
2023 Q3 71 23.0 M $171 M
2023 Q2 81 24.7 M $205 M
2023 Q1 70 23.4 M $312 M
2022 Q4 67 22.0 M $327 M
2022 Q3 44 9.83 M $88.8 M
2022 Q2 34 5.73 M $17.2 M
2022 Q1 38 6.21 M $41.7 M
2021 Q4 41 7.37 M $39.7 M
2021 Q3 38 7.21 M $63.8 M